Aly-Khan Lalani, MD of Dana-Farber Cancer Institute discusses the next steps for his study, which include combining c-met targeted therapies with immunotherapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 4573: Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression